Register Now: Engineering LNP's Beyond the Liver for Genetic Medicines
|Articles|September 11, 2019

GE Healthcare to Partner with NIBRT for Biopharma Education Program

The companies plan to create a new curriculum focusing on single-use applications training, cell therapy technology, process efficiency strategies, process development methodologies, and chromatography proficiency.

GE Healthcare (GEHC) announced on Sept. 11, 2019 that it is teaming up with the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, to deliver educational programming on biopharmaceutical and cell therapy development and manufacturing. 

The companies plan to share GEHC’s Fast Trak training and education curriculum and will co-develop a new curriculum to help the global biomanufacturing industry meet the needs of changing technologies and modalities,. The new curriculum will feature single-use applications training, cell-therapy technology, process efficiency strategies, process development methodologies, and chromatography proficiency.

“At NIBRT, we pride ourselves on our best-in-class education and training programs that support the thriving biopharmaceutical industry. By working with GEHC we will be able to leverage their biomanufacturing expertise to create exciting new programs designed to meet the global demand for talent,” said Killian O’Driscoll, director of projects, NIBRT, in the press release.

Courses will be available at the Jefferson Institute of Bioprocessing in Philadelphia, PA, the NIBRT facility in Dublin, and at GEHC Fast Trak locations in the United States, South Korea, Sweden, India, China, Turkey, Japan, and Singapore.

Source: GE Healthcare

 


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Drug Digest: Expedited Regulatory Pathways for Biologics
Experts Harpreet Singh and Steven Quay discuss FDA expedited regulatory pathways for biologics, including Fast Track, Breakthrough Therapy, RMAT, Real-Time Oncology Review, and the National Priority Voucher Pilot Program, and explain how these mechanisms can accelerate development without lowering evidentiary standards.